Key papers in Endocrinology, Diabetes and Metabolism
Pofolia’s corpus holds 84 papers from the Endocrinology, Diabetes and Metabolism subfield (2012–2023). The list below starts with the most cited.
Most cited
Ranked by citation count. Because citations accumulate over time, this list naturally leans towards work published a few years ago; for where the field is now, see “recently added”.
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
Thyroid · 2015 · Q1 · SJR 1.00 · FWCI 682.09 · 16,488 citations · Open access
These updated guidelines provide evidence-based recommendations for the diagnosis and management of thyroid nodules and differentiated thyroid cancer in adults.
International Diabetes Federation 2017
Journal of Diabetes · 2018 · Q1 · SJR 1.00 · FWCI 730.85 · 13,554 citations · Open access
This article is a news feature from the Journal of Diabetes, reviewing the latest developments in diabetes and obesity care.
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
New England Journal of Medicine · 2015 · Q1 · SJR 18.00 · FWCI 564.39 · 12,062 citations · Open access
In patients with type 2 diabetes and high cardiovascular risk, empagliflozin added to standard care significantly reduced the primary composite outcome of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 14% (hazard ratio, 0.86) over a median of 3.1 years.
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
New England Journal of Medicine · 2017 · Q1 · SJR 18.00 · FWCI 475.78 · 7,801 citations · Open access
In patients with type 2 diabetes and high cardiovascular risk, canagliflozin significantly reduced major cardiovascular events by 14% compared to placebo over nearly 4 years.
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
New England Journal of Medicine · 2016 · Q1 · SJR 18.00 · FWCI 573.75 · 7,419 citations · Open access
In patients with type 2 diabetes and high cardiovascular risk, liraglutide significantly reduced the primary composite outcome of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke compared to placebo.
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
New England Journal of Medicine · 2019 · Q1 · SJR 18.00 · FWCI 475.97 · 6,927 citations · Open access
Dapagliflozin significantly reduced the risk of worsening heart failure or cardiovascular death by 26% in patients with heart failure and reduced ejection fraction, regardless of diabetes status.
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
New England Journal of Medicine · 2016 · Q1 · SJR 18.00 · FWCI 364.88 · 6,673 citations · Open access
Once-daily oral semaglutide demonstrated non-inferiority to placebo in reducing major adverse cardiovascular events in patients with type 2 diabetes and high cardiovascular risk.
Heart Disease and Stroke Statistics—2016 Update
Circulation · 2015 · Q1 · SJR 8.00 · FWCI 686.87 · 6,643 citations
This annual update compiles the latest statistics on heart disease, stroke, and related conditions, serving as a crucial resource for data on cardiovascular health and its burdens.
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
New England Journal of Medicine · 2018 · Q1 · SJR 18.00 · FWCI 404.04 · 6,343 citations · Open access
In patients with type 2 diabetes, dapagliflozin did not significantly reduce major adverse cardiovascular events (MACE) but did lower the rate of cardiovascular death or hospitalization for heart failure by 17% compared to placebo.
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
New England Journal of Medicine · 2019 · Q1 · SJR 18.00 · FWCI 441.56 · 6,036 citations · Open access
In patients with type 2 diabetes and kidney disease, canagliflozin significantly reduced the risk of kidney failure and major cardiovascular events by 30% compared to placebo over a median follow-up of 2.62 years.
Antihyperlipidemic and Biochemical Activities of Mcy Protein in Streptozotocin Induced Diabetic Rats
Cellular Physiology and Biochemistry · 2015 · Q3 · FWCI 389.60 · 5,950 citations · Open access
A novel Mcy protein from Momordica cymbalaria significantly reduced fasting blood glucose and serum/tissue lipid levels in diabetic rats, while also normalizing liver and kidney function markers.
Dapagliflozin in Patients with Chronic Kidney Disease
New England Journal of Medicine · 2020 · Q1 · SJR 18.00 · FWCI 347.80 · 5,265 citations · Open access
Dapagliflozin significantly reduced the risk of major kidney and cardiovascular events in patients with chronic kidney disease, regardless of diabetes status.
Heart Disease and Stroke Statistics—2014 Update
Circulation · 2013 · Q1 · SJR 8.00 · FWCI 582.98 · 5,230 citations · Open access
This annual update compiles the latest national data on heart disease, stroke, and related vascular conditions, presenting a comprehensive resource for understanding morbidity, mortality, risk factors, and care.
Heart Disease and Stroke Statistics—2013 Update
Circulation · 2012 · Q1 · SJR 8.00 · FWCI 537.06 · 5,189 citations · Open access
This annual update compiles the latest national statistics on heart disease, stroke, and related vascular diseases, presenting a comprehensive overview of morbidity, mortality, risk factors, and costs.
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
New England Journal of Medicine · 2020 · Q1 · SJR 18.00 · FWCI 394.72 · 5,074 citations · Open access
Empagliflozin significantly reduced the risk of cardiovascular death or hospitalization for worsening heart failure by 25% in patients with heart failure and reduced ejection fraction, regardless of diabetes status.
2. Classification and Diagnosis of Diabetes:<i>Standards of Medical Care in Diabetes—2022</i>
Diabetes Care · 2021 · Q1 · SJR 7.00 · FWCI 463.18 · 4,748 citations · Open access
The American Diabetes Association (ADA) annually updates its "Standards of Medical Care in Diabetes," providing current clinical practice recommendations for diabetes care, treatment goals, and quality evaluation.
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
New England Journal of Medicine · 2021 · Q1 · SJR 18.00 · FWCI 431.93 · 4,661 citations · Open access
Empagliflozin significantly reduced the combined risk of cardiovascular death or hospitalization for heart failure by 21% in patients with preserved ejection fraction heart failure.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
New England Journal of Medicine · 2021 · Q1 · SJR 18.00 · FWCI 314.08 · 4,614 citations
A 68-week trial found that once-weekly semaglutide at 2.4 mg, combined with lifestyle changes, led to a significant average weight loss of 14.9% in adults with overweight or obesity, compared to 2.4% with placebo.
Standards of Medical Care in Diabetes—2013
Diabetes Care · 2012 · Q1 · SJR 7.00 · FWCI 426.20 · 4,428 citations · Open access
This document outlines the 2013 standards for diabetes care, emphasizing evidence-based guidelines derived from high-quality research.
Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants
The Lancet · 2016 · FWCI 418.19 · 4,391 citations · Open access
Global age-standardized diabetes prevalence nearly doubled from 4.3% in men and 5.0% in women in 1980 to 9.0% and 7.9% respectively in 2014, leading to a near quadrupling of affected adults worldwide.
Recently added
2. Diagnosis and Classification of Diabetes:<i>Standards of Care in Diabetes—2024</i>
Diabetes Care · 2023 · Q1 · SJR 7.00 · FWCI 278.88 · 1,828 citations · Open access
The American Diabetes Association (ADA) has updated its annual "Standards of Care in Diabetes—2024," providing current clinical practice recommendations for diabetes diagnosis, treatment goals, and quality assessment.
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
New England Journal of Medicine · 2023 · Q1 · SJR 18.00 · FWCI 413.82 · 2,717 citations
Weekly 2.4 mg semaglutide reduced major adverse cardiovascular events by 20% (HR 0.80) compared to placebo in overweight or obese adults with pre-existing cardiovascular disease but no diabetes.
Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021
The Lancet · 2023 · FWCI 660.37 · 4,326 citations · Open access
In 2021, 529 million people had diabetes globally, projected to reach over 1.31 billion by 2050, with high BMI accounting for 52.2% of type 2 diabetes burden.
Empagliflozin in Patients with Chronic Kidney Disease
New England Journal of Medicine · 2022 · Q1 · SJR 18.00 · FWCI 255.59 · 2,449 citations · Open access
Empagliflozin significantly reduced the risk of kidney disease progression or cardiovascular death by 28% (HR 0.72) compared to placebo in a broad range of chronic kidney disease (CKD) patients over a median of 2 years.
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Diabetes Care · 2022 · Q1 · SJR 7.00 · FWCI 198.96 · 1,982 citations · Open access
New ADA/EASD guidelines emphasize social determinants of health, weight management, and cardiorenal protection with SGLT2 inhibitors and GLP-1 RAs for type 2 diabetes.
Add this field to your daily feed
Pick your interests and new work in your area arrives every day, summarised. Full summaries live in the app.
Open the app